Be in the know about the most anticipated aesthetic procedure.
How does ellacor work?
Ellacor uses hollow needles to remove micro-cores of skin, resulting in an improved appearance of wrinkles without evidence of scarring.1,2
How is ellacor different from other skin revitalization devices?
Ellacor removes micro-portions of excess skin to achieve an improvement in the appearance of wrinkles, whereas many other skin revitalization devices use heat generated by laser, radio frequency and ultrasound energy to induce intentional thermal injury to the skin.
How many procedures will I need?
As every patient has different needs, please speak with your physician to determine the treatment plan that is right for you. In the clinical trial, most patients underwent a series of three procedures spaced approximately 30 days apart.
How long is a typical procedure?
An ellacor procedure typically takes about 30 minutes or less.
Is the procedure painful?
Your physician will provide you with appropriate anesthesia prior to the procedure to make you more comfortable. Most patients in our clinical trial reported pain during the procedure as less than 2 on a 0-10 scale.1
Is the recovery time long?
Recovery time ranges from a few days to weeks, which can vary by patient and treatment settings. Since every patient heals at different rates, patient results and experience may vary. Please consult with your ellacor provider for more information.
Does ellacor use laser, radio frequency, or ultrasound energy?
The ellacor system is able to remove skin on the microscale without the use of thermal energy.
How is ellacor different from microneedling?
Microneedling uses small needles to injure the tissue, but skin is not removed during this procedure – the tissue is temporarily displaced. Ellacor is the first device to actually remove skin on the microscale.
Can I receive ellacor if I have a darker skin tone?
Because darker skin types (V and VI) may react differently to aesthetic treatments than lighter skin types (I-IV), a separate clinical study is needed to evaluate the proper protocols for using ellacor on darker skin types.
How should I prepare for the ellacor procedure?
Your physician will provide a complete list of requirements and guidelines during your consultation.
How do I know whether ellacor is right for me?
It is best to make an appointment to speak directly with your physician to see if you’re a candidate for ellacor.
The ellacor® System with Micro-Coring® technology is indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
Your medical professional will discuss the following side effects with you prior to treatment. Proper pre- and post-treatment care reduces the risk of these side effects; however, some conditions may or may not resolve over time. Side effects associated with this procedure may include: redness, swelling, bruising, burning, dryness, roughness, tightness/pulling of skin, crusting, pain/discomfort, tenderness, tingling, bleeding, numbness, skin peeling, or circular marks on skin.
Other side effects not commonly observed with this procedure may include: itching, hyper/hypo pigmentation, hematoma, infection, scarring, skin irregularities, skin necrosis, uneven appearance of the treated regions (left and right sides of face), or anesthesia toxicity (anesthesia-related complications may include allergic reaction and possibly death).
The ellacor® procedure should not be used for the treatment of areas of skin with dermatosis (e.g. skin tumors, keloids or in case of predisposition to keloids, solar keratosis, warts, or birthmarks), area within the bony orbital rim; mucous membranes; areas where silicone or synthetic material is implanted.
The ellacor® procedure should not be used on patients that are pregnant or nursing mothers, suffering from open wounds, sores, or irritated skin in the treatment area, have an allergy to stainless steel or allergy to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine. Patients that have a history or presence of any clinically significant bleeding disorder, have dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus should not be treated with the ellacor® procedure. Additionally, patients that have systemic infections or acute local skin infections such as Hepatitis disorders type A, B, C, D, E or F or HIV infection, take a high dose of anti-coagulants or blood-thinning substances (e.g. aspirin, nonsteroidal anti-inflammatory drugs, NSAIDs, warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days), are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area, have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old, have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months, or have scars less than six (6) months old in the treatment area should not be treated with the ellacor® procedure.
Appropriateness for treatment is based on the clinical assessment of the patient by the treating physician. Use caution when treating patients with the following conditions or taking the following medications: